Sphinx cuts a new deal with Lilly

The latest company to retrieve some of its technology is Sphinx Pharmaceuticals Corp., which on Friday said it restructured its agreement with Eli Lilly and Co. covering the protein kinase C (PKC) family of intracellular enzymes. PKC mediates cell functions including inflammation and cell proliferation.

SPHX signed the agreement in October 1991, when it needed the development capabilities of a partner, validation and cash, said Clayton Duncan, president and CEO...